Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Get Free Report) have received a consensus recommendation of “Hold” from the eight ratings firms that are currently covering the company, Marketbeat reports. Six equities research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $17.60.
A number of brokerages have issued reports on AMLX. Mizuho cut their price target on Amylyx Pharmaceuticals from $4.00 to $3.00 and set a “neutral” rating for the company in a research note on Tuesday, May 14th. The Goldman Sachs Group increased their price target on Amylyx Pharmaceuticals from $3.00 to $4.00 and gave the stock a “neutral” rating in a research note on Friday, July 12th. Finally, HC Wainwright reiterated a “buy” rating and issued a $8.00 price target on shares of Amylyx Pharmaceuticals in a research note on Wednesday, July 10th.
Get Our Latest Research Report on AMLX
Institutional Inflows and Outflows
Amylyx Pharmaceuticals Price Performance
NASDAQ:AMLX opened at $1.97 on Wednesday. The firm has a market capitalization of $133.98 million, a price-to-earnings ratio of -1.84 and a beta of -0.64. Amylyx Pharmaceuticals has a one year low of $1.58 and a one year high of $23.72. The business has a fifty day moving average price of $1.83 and a 200-day moving average price of $6.22.
Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Free Report) last posted its quarterly earnings data on Friday, May 10th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of $0.24 by ($0.70). The company had revenue of $88.64 million during the quarter, compared to analysts’ expectations of $113.26 million. Amylyx Pharmaceuticals had a positive return on equity of 4.14% and a negative net margin of 17.86%. During the same quarter last year, the company earned $0.02 earnings per share. On average, equities research analysts expect that Amylyx Pharmaceuticals will post -1.36 earnings per share for the current fiscal year.
About Amylyx Pharmaceuticals
Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.
See Also
- Five stocks we like better than Amylyx Pharmaceuticals
- What is the Australian Securities Exchange (ASX)
- Is Crypto Cool Again? What Stocks You Should Be Watching
- Business Services Stocks Investing
- Why Call Options Volume for These 2 Stocks Spiked Together
- What is Forex and How Does it Work?
- MarketBeat Week in Review – 7/22 – 7/26
Receive News & Ratings for Amylyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amylyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.